Scoop: Blackstone is providing as much as $1.3 billion to Apogee to help the biotech company advance a potential competitor to Dupixent
https://t.co/kymTVI9eXH
In one of the first moves of the post-Makary era, FDA has scheduled a meeting of outside experts to discuss Moderna's controversial mRNA flu vaccine application. w/ @gerryfsmith https://t.co/P7CCi11lE6
New: US officials are working with a small biotech company, Mapp Biopharmaceutical, to provide an experimental treatment that may be used in patients exposed to Ebola. https://t.co/WYCtP6oTM1
New: Can AI Drug Development Live Up to the Hype?
The industry is pouring billions into the idea that it can make the process faster and more predictable, but there's reason for caution:
https://t.co/Y8PeSpmYHR
More turnover at FDA: The agency is replacing the head of its vaccine and gene therapy division with FDA adviser Karim Mikhail, while current acting director Katherine Szarama will stay at the agency. Other changes here:
https://t.co/PBpy2U0Bne
Marty Makary’s exit as head of the FDA is giving the biotech industry hope for stability after months of turmoil.
"It’s been a circus," one analyst said, adding that he's looking forward to "a new leader and less drama."
https://t.co/y0EPiyjnsb
Scoop: Blackstone is investing $250 million in the biotech startup Anagram Therapeutics, part of the private equity giant’s strategy to own more cutting-edge drugmakers.
https://t.co/llCuCCTgq5
Marty Makary was supposed to be one of President Donald Trump’s more conventional advisers. Instead, tension and controversy have clouded his tenure. Insiders say one more high-profile misstep could put the FDA commissioner’s job at risk. https://t.co/DZKkbtZRLa
NEW: Dylan Field Turner had cycled through antidepressants for a decade before trying Spravato. “It shakes things loose,” he said. “It’s like changing your spark plugs.”
More here on J&J’s blockbuster depression treatment for @business https://t.co/Xdv1hXvLe4
Bristol Myers paid $14 billion for a neuroscience drug with the potential to transform the treatment of schizophrenia, an overlooked area of mental health care. It’s not working out https://t.co/nVKvVZvfmW
Novartis, Amgen and Eli Lilly are all betting that slashing levels of a particularly bad form of cholesterol called Lp(a) will cut a person's risk of heart attack and create the next blockbuster drugs for heart disease
https://t.co/nFktyjWYrZ
New: When Cobenfy was approved more than 18 months ago, it was celebrated as a game-changer for the 23 million people worldwide with schizophrenia. But after more than a full year on the market, it has struggled to gain traction. https://t.co/S7F8cl4m5b
Scoop: Mark Cuban’s low-cost online pharmacy will sell the blockbuster blood thinner Eliquis starting next week, a win for the billionaire’s effort to transform the way drugs are sold in the US. https://t.co/wZ97VwUwOD
NEW: Regeneron will offer a gene therapy that restored hearing for a small number of profoundly deaf children at no cost after US regulators approved the treatment. https://t.co/ZSftxAmmOZ
Trump's Plan to Cut US Drug Prices Backfires for Europe
Who could have predicted? Rather than endanger their US profits, some drugmakers withhold new medicines from European markets. 🎁from @gerryfsmith@ashleighfurlong and @fabiennekatrin https://t.co/2xuAh4FQu8
And we finally have a CDC director nominee: Trump picks Erica Schwartz, former deputy surgeon general to lead the top public health agency after a year of chaos. More details to come. @business https://t.co/zQa4KJcJrD